Our proprietary Bottle-brush Analogue Macromolecule (or BAM) has a bioinspired cylindrical shape capable of deeply penetrating into diseased tumor tissues.
With the added targeting capability of a monoclonal antibody (mAb) in the form of a Antibody-BAM Conjugate (or ABC), Window Therapeutics has created a therapeutic agent designed to kill cancer cells exclusively. The ABC construct leverages five main components:
Once there, BAM’s chemical linkers respond to signals from the cancer cells, causing them to release and switch the drugs “ON”.
When not in a cancer site BAM’s linkers remain intact, keeping the drug switched “OFF” thus avoiding toxicity.
Window Therapeutics, through conjugation of the versatile BAM-Platform with monoclonal antibodies (mAbs), has invented a new Antibody-Drug Conjugate paradigm. Antibody–BAM Conjugates (ABC) enable high Drug Antibody Ratios (DAR) from 10 to over 100, without effecting the binding affinity of the mAb. The BAM enables conjugation of molecularly targeted therapeutics, chemotherapies, immunotherapies, etc. as single or combination drug payloads. Each drug payload is linked to the BAM-Platform with specially designed linkers with specific release triggers and rates.
Augment efficacy, tolerability and ease of administration
The BAM technology can be applied as part of the life cycle management strategy for currently marketed or established drugs. Whether through 505b2 registration, 505b1 or as novel NCE’s, the application of Window’s technologies may dramatically augment the efficacy, tolerability and ease of patient administration or compliance for already approved drugs.
Recover, rehabilitate struggling programs
Further, Window Therapeutics technologies can recover and ‘rehabilitate’ drugs or drug programs that are otherwise struggling due to narrow therapeutic windows in clinical or preclinical development.
Reinvent abandoned drugs
Window Therapeutics can also reinvent drugs that, despite high potency, are abandoned in the drug discovery phase due to unfavorable solubility or generally poor ADME properties. The BAM platform’s physicochemical properties wholly supplant those of the conjugated drug, enabling promising therapeutic profiles and treatment options for patients.